Brief: Schott Pharma Maintains Full-Year Guidance For 2025
April 10 (Reuters) - SCHOTT PHARMA AG & CO KGAA 1SXP.DE: PRELIMINARY Q2 2025 FIGURES EXCEED CAPITAL MARKET EXPECTATIONS MAINTAINS FULL-YEAR GUIDANCE FOR 2025 EXPECTS Q2 2025 EBITDA OF EUR 72M EXPECTS Q2 2025 REVENUES OF EUR 252M Source text: ID:nEQ2QTpNza Further company coverage: 1SXP.DE (Gdansk Newsroom) (((( gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));))
Recent news on SCHOTT Pharma AG & Co. KGaA
See all newsEurope Research Roundup: GSK, Schott Pharma, Vodafone
SCHOTT Pharma rises after J.P. Morgan initiates with 'Overweight'
Schott Pharma rises after Barclays upgrades to 'overweight' on accelerating growth outlook
Europe Research Roundup: Adyen, GYM Group, Rolls Royce
Brief: Schott Pharma - Confirms Recently Increased 2026 Financial Year Guidance